Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor

IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis

(2014) L. Skov et al.   JOURNAL OF IMMUNOLOGY

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy

(2011) C. Pinto et al.   ONCOLOGIST

Epidermal growth factor receptor inhibitors in oncology

(2010) Igor Vivanco et al.   CURRENT OPINION IN ONCOLOGY

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

(2010) Cheryl Ho et al.   INVESTIGATIONAL NEW DRUGS

Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines

(2009) S.S. Han et al.   BRITISH JOURNAL OF DERMATOLOGY

Tumor Necrosis Factor-  and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

(2009) D. Surguladze et al.   CANCER RESEARCH

A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration

(2009) Thomas K. Hoffmann et al.   INTERNATIONAL JOURNAL OF CANCER

The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation

(2007) Saveria Pastore et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY